Search Results for "Growth"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Growth. Results 101 to 107 of 107 total matches.

Comparison Table: Some Drugs for HFrEF (online only)

   
The Medical Letter on Drugs and Therapeutics • Mar 08, 2021  (Issue 1619)
Have been associated with fetal growth restriction, but beta-1-selective drugs (e.g., bisoprolol, metoprolol ...
View the Comparison Table: Some Drugs for HFrEF
Med Lett Drugs Ther. 2021 Mar 8;63(1619):e1-14 |  Show IntroductionHide Introduction

Drugs for GERD and Peptic Ulcer Disease

   
The Medical Letter on Drugs and Therapeutics • Apr 04, 2022  (Issue 1647)
and reversible inhibition of bone growth when taken during pregnancy. Levofloxacin also should generally ...
Gastroesophageal reflux disease (GERD) is the most common GI condition encountered in the outpatient setting; it affects about 20% of people in the US.
Med Lett Drugs Ther. 2022 Apr 4;64(1647):49-56 |  Show IntroductionHide Introduction

Drugs for Opioid Use Disorder

   
The Medical Letter on Drugs and Therapeutics • Sep 04, 2023  (Issue 1684)
of complications including preeclampsia, miscarriage, reduced fetal growth, fetal death, and premature delivery ...
Opioid use disorder is a chronic, relapsing disease with physical and psychiatric components. It is associated with economic hardship, social isolation, incarceration, increased rates of blood-borne infections such as HIV and viral hepatitis, adverse pregnancy outcomes, and increased mortality. According to the NIH, there were 80,411 deaths involving an opioid in the US in 2021, more than in any previous year. Several guidelines on the management of opioid use disorder are available; all recommend maintenance pharmacotherapy as the standard of care.
Med Lett Drugs Ther. 2023 Sep 4;65(1684):137-44   doi:10.58347/tml.2023.1684a |  Show IntroductionHide Introduction

Comparison Table: Some Oral Antiseizure Medications (online only)

   
The Medical Letter on Drugs and Therapeutics • Aug 05, 2024  (Issue 1708)
, cardiac defects, dysmorphic skull/facial features, nail and digit hypoplasia, growth abnormalities ...
View the Comparison Table: Some Oral Antiseizure Medications
Med Lett Drugs Ther. 2024 Aug 5;66(1708):e133-40   doi:10.58347/tml.2024.1708b |  Show IntroductionHide Introduction

Drugs for Plaque Psoriasis

   
The Medical Letter on Drugs and Therapeutics • Sep 30, 2024  (Issue 1712)
for treatment of psoriasis involving the face and intertriginous areas. It regulates production and growth ...
Mild to moderate plaque psoriasis can be treated with topical drugs and phototherapy. Patients with moderate to severe disease generally require systemic therapy. Guidelines for the treatment of psoriasis with topical therapy, phototherapy, and systemic drugs have recently been published.
Med Lett Drugs Ther. 2024 Sep 30;66(1712):153-60   doi:10.58347/tml.2024.1712a |  Show IntroductionHide Introduction

Drugs for Chronic Heart Failure

   
The Medical Letter on Drugs and Therapeutics • Jun 14, 2021  (Issue 1626)
renal failure and death. Beta blockers have been associated with fetal growth restriction, but beta-1 ...
Among patients with chronic heart failure, those with a left ventricular ejection fraction (LVEF) ≤40% are considered to have heart failure with reduced ejection fraction (HFrEF). Patients with a LVEF ≥50% are considered to have heart failure with preserved ejection fraction (HFpEF). Those with a LVEF of 41-49% are an intermediate group more similar to patients with HFpEF.
Med Lett Drugs Ther. 2021 Jun 14;63(1626):89-96 |  Show IntroductionHide Introduction

Opioids for Pain

   
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022  (Issue 1665)
delivery, poor fetal growth, stillbirth, birth defects (e.g., neural tube defects, congenital heart ...
A new CDC guideline for prescribing opioids for pain recently became available. Nonopioid drugs for pain were reviewed in a previous issue.
Med Lett Drugs Ther. 2022 Dec 12;64(1665):193-200 |  Show IntroductionHide Introduction